Your request has been received.
We will send you more information as it becomes available.
days to go: ASP+6% CMS reimbursement for proven non-opioids used in all outpatient surgical settings is coming January 1, 2025.
Multimodal analgesia is the utilization of multiple pain management modalities for more effective pain control, which can lead to enhanced clinical and economic benefits
Decreases In
Improvement In
EXPAREL encapsulates bupivacaine in a proprietary multivesicular liposome (pMVL) delivery technology to reliably release bupivacaine over time
Targets the pain signal at the surgical site
Reduces the need for opioids* while providing long-lasting postsurgical pain control
Avoids external barriers to earlier ambulation, such as catheters, pumps, devices, and medicines that cause impairment
*The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials
AAOMS
Oral/Maxillofacial
AAOMS also supports multimodal pain management strategies, such as the use of long-acting local anesthetics during surgery and NSAIDs either presurgically and/or postsurgically for acute pain control in conjunction with the judicious use of opioids or as a substitute.7
ASCRS, SAGES
Colorectal Surgery
Strong recommendation for the use of a perisurgical multimodal, opioid-sparing, pain management plan, noting that liposomal bupivacaine wound infiltration and transversus abdominis plane (TAP) blocks “have shown promising results in patients undergoing open and laparoscopic colorectal surgery.”8
ERAS Society
Breast Reconstruction
Strong recommendation for the use of multimodal’ opioid-sparing postsurgical pain bupivacaine regimens, noting that “a single injection of liposomal bupivacaine lasts for several days, potentially avoiding the need for catheter-based infusions.”9
ERAS Society
Gynecologic Oncology
Strong recommendation for a multimodal postsurgical analgesic protocol using non-opioid oral medications and incisional injection of local anesthetic to decrease the need for systemic medications, stating that “incisional infiltration with either bupivacaine or liposomal bupivacaine has no systemic side effects when used appropriately and should be incorporated into all ERAS protocols as a component of multimodal analgesia.”10
ERAS Society, ESTS
Thoracic Surgery
Recommends peripheral nerve blocks over thoracic epidural, and notes that “liposomal bupivacaine also shows promise when delivered as multilevel intercostal injections potentially providing blockade of intercostal nerves for up to 96 hours.”11
AAOMS, American Association of Oral and Maxillofacial Surgeons; ASCRS, American Society of Colon and Rectal Surgeons; SAGES, Society of American Gastrointestinal and Endoscopic Surgeons; ERAS, enhanced recovery after surgery; ESTS, European Society of Thoracic Surgeons.
ASP, average sales price; CMS, Centers for Medicare and Medicaid Services.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.
Please refer to full Prescribing Information.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration
This website uses cookies to give you a better browsing experience. By clicking the "Allow all cookies" button, you agree to our use of cookies. For additional information, see our Cookie Notice.